While SIK inhibitors have been shown to increase prednisolone sensitivity in ETP-ALL cell models, it will be interesting to assess in the future whether this inhibitor can also target a subgroup of patients with non-immature immunophenotype who express high MEF2C and does not possess alterations in CDKN2A/B. The gene discussed is CDKN2A; the disease is acute lymphoblastic leukemia.